RCBTB2

Summary

RCBTB2 (RCC1 and BTB domain containing protein 2, HGNC:1914) is a protein-coding gene on chromosome 13q14.2, encoding RCC1 and BTB domain-containing protein 2 (O95199).

This gene encodes a protein containing two C-terminal BTB/POZ domains that is related to regulator of chromosome condensation (RCC). The encoded protein may act as a guanine nucleotide exchange factor. This gene is observed to be lost or underexpressed in prostate cancers. There is a pseudogene of this gene on chromosome 10. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 1102 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 80 total
• MANE Select transcript: NM_001268

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1914
Approved symbol	RCBTB2
Name	RCC1 and BTB domain containing protein 2
Location	13q14.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000136161
Ensembl biotype	protein_coding
OMIM	603524
Entrez	1102

Gene structure

Transcript identifiers

Ensembl transcripts: 20 — 17 protein_coding, 3 protein_coding_CDS_not_defined

ENST00000344532, ENST00000430805, ENST00000462703, ENST00000481144, ENST00000544492, ENST00000544904, ENST00000611827, ENST00000874757, ENST00000874758, ENST00000874759, ENST00000874760, ENST00000874761, ENST00000874762, ENST00000874763, ENST00000929084, ENST00000959816, ENST00000959817, ENST00000959818, ENST00000959819, ENST00000959820

RefSeq mRNA: 10 — MANE Select: NM_001268 NM_001268, NM_001286830, NM_001286831, NM_001286832, NM_001352424, NM_001352425, NM_001352426, NM_001352427, NM_001352428, NM_001352429

CCDS: CCDS73570, CCDS73571, CCDS73572, CCDS9411

Canonical transcript exons

ENST00000344532 — 15 exons

Exon	Start	End
ENSE00000682432	48512016	48512174
ENSE00000836834	48510629	48510771
ENSE00001386639	48524659	48524757
ENSE00001599088	48499621	48499760
ENSE00001695074	48502724	48502914
ENSE00001770653	48501742	48501868
ENSE00001800297	48496191	48496321
ENSE00001919905	48533028	48533080
ENSE00001926142	48488963	48490251
ENSE00002293750	48521898	48521962
ENSE00003505412	48512729	48512895
ENSE00003506298	48515205	48515355
ENSE00003641170	48511770	48511877
ENSE00003666887	48522308	48522403
ENSE00003691558	48515586	48515741

Expression profiles

Bgee: expression breadth ubiquitous, 273 present calls, max score 97.73.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 9.2180 / max 133.5083, expressed in 1539 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
137283	4.5588	1450
137284	1.6692	393
137260	1.6148	290
137282	0.5879	283
137258	0.3373	133
137261	0.2416	91
137259	0.1666	89
137285	0.0419	27

Top tissues by expression

286 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	97.73	gold quality
monocyte	CL:0000576	97.46	gold quality
mononuclear cell	CL:0000842	97.30	gold quality
leukocyte	CL:0000738	97.03	gold quality
cranial nerve II	UBERON:0000941	95.83	gold quality
parietal pleura	UBERON:0002400	95.23	gold quality
visceral pleura	UBERON:0002401	94.81	gold quality
pleura	UBERON:0000977	94.73	gold quality
choroid plexus epithelium	UBERON:0003911	94.29	gold quality
pigmented layer of retina	UBERON:0001782	94.02	gold quality
seminal vesicle	UBERON:0000998	93.70	gold quality
ganglionic eminence	UBERON:0004023	92.87	gold quality
ventricular zone	UBERON:0003053	92.83	gold quality
granulocyte	CL:0000094	92.68	gold quality
parotid gland	UBERON:0001831	91.32	gold quality
esophagus squamous epithelium	UBERON:0006920	91.32	gold quality
blood	UBERON:0000178	91.24	gold quality
germinal epithelium of ovary	UBERON:0001304	91.08	gold quality
gingival epithelium	UBERON:0001949	90.98	gold quality
tibia	UBERON:0000979	90.59	gold quality
nephron tubule	UBERON:0001231	90.58	gold quality
gingiva	UBERON:0001828	90.33	gold quality
epithelium of esophagus	UBERON:0001976	90.20	gold quality
minor salivary gland	UBERON:0001830	90.03	gold quality
embryo	UBERON:0000922	90.01	gold quality
saliva-secreting gland	UBERON:0001044	90.01	gold quality
renal glomerulus	UBERON:0000074	89.59	gold quality
mouth mucosa	UBERON:0003729	89.49	gold quality
squamous epithelium	UBERON:0006914	89.44	gold quality
metanephros	UBERON:0000081	89.28	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-GEOD-111727	yes	1289.30
E-MTAB-5061	yes	6.22
E-MTAB-6075	no	311.98
E-MTAB-7303	no	47.32
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

99 targeting RCBTB2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-512-3P	99.97	67.35	1049
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-589-3P	99.91	69.62	2088
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-374B-5P	99.90	69.98	2734
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-576-5P	99.84	70.46	2582
HSA-MIR-520F-3P	99.82	71.32	1216
HSA-MIR-323A-3P	99.79	70.30	1739
HSA-MIR-2052	99.79	69.37	2031
HSA-MIR-4713-5P	99.78	67.80	1794
HSA-MIR-320A-3P	99.77	69.73	2107
HSA-MIR-320B	99.77	69.73	2107
HSA-MIR-320C	99.77	69.73	2107
HSA-MIR-320D	99.77	69.73	2107

Literature-anchored findings (GeneRIF, showing 2)

• decreased expression in prostate cancer associated with the difference in frequency of variant isoforms between normal and neoplastic prostate tissues places it in a pivotal role or possibly adjacent to a gene with that role in prostate cancer evolution (PMID:12115502)
• Expression of CLLD7 and CHC1L Proteins in Oral Epithelial Dysplasia in a Group of Thai Patients. (PMID:38679985)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	rcbtb2	ENSDARG00000090687
mus_musculus	Rcbtb2	ENSMUSG00000022106
rattus_norvegicus	Rcbtb2	ENSRNOG00000015054
drosophila_melanogaster	ca	FBGN0000247
drosophila_melanogaster	Rcc1	FBGN0002638
drosophila_melanogaster	CG7420	FBGN0031344
caenorhabditis_elegans		WBGENE00004304

Paralogs (9): ALS2 (ENSG00000003393), HERC1 (ENSG00000103657), SERGEF (ENSG00000129158), RCBTB1 (ENSG00000136144), RPGR (ENSG00000156313), RCCD1 (ENSG00000166965), RCC2 (ENSG00000179051), RCC1 (ENSG00000180198), RCC1L (ENSG00000274523)

Protein

Protein identifiers

RCC1 and BTB domain-containing protein 2 — O95199 (reviewed: O95199)

Alternative names: Chromosome condensation 1-like, RCC1-like G exchanging factor, Regulator of chromosome condensation and BTB domain-containing protein 2

All UniProt accessions (3): B4DWG0, B4E372, O95199

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Cytoplasmic vesicle. Secretory vesicle. Acrosome.

Domain organisation. The BTB domain might play a role in targeting to acrosomal vesicles.

Isoforms (2)

UniProt ID	Names	Canonical?
O95199-1	1	yes
O95199-2	2

RefSeq proteins (10): NP_001259, NP_001273759, NP_001273760, NP_001273761, NP_001339353, NP_001339354, NP_001339355, NP_001339356, NP_001339357, NP_001339358 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000210	BTB/POZ_dom	Domain
IPR000408	Reg_chr_condens	Repeat
IPR009091	RCC1/BLIP-II	Homologous_superfamily
IPR011333	SKP1/BTB/POZ_sf	Homologous_superfamily
IPR051625	Signaling_Regulatory_Domain	Family
IPR058923	RCC1-like_dom	Domain

Pfam: PF00651, PF25390

UniProt features (11 total): repeat 6, sequence variant 2, chain 1, domain 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O95199-F1	90.45	0.73

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 263 (showing top): GOBP_HEPATICOBILIARY_SYSTEM_DEVELOPMENT, GOCC_SECRETORY_GRANULE, MODULE_45, GOBP_LYMPH_NODE_DEVELOPMENT, THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_DN, TAKADA_GASTRIC_CANCER_COPY_NUMBER_DN, GOBP_DIGESTIVE_SYSTEM_DEVELOPMENT, DEURIG_T_CELL_PROLYMPHOCYTIC_LEUKEMIA_DN, ODONNELL_TARGETS_OF_MYC_AND_TFRC_UP, GOBP_HEMATOPOIETIC_OR_LYMPHOID_ORGAN_DEVELOPMENT, COATES_MACROPHAGE_M1_VS_M2_UP, BASSO_HAIRY_CELL_LEUKEMIA_UP, ZHOU_INFLAMMATORY_RESPONSE_LIVE_DN, SCHLOSSER_SERUM_RESPONSE_DN, AACTTT_UNKNOWN

GO Biological Process (5): liver development (GO:0001889), cell population proliferation (GO:0008283), lymph node development (GO:0048535), spleen development (GO:0048536), digestive tract development (GO:0048565)

GO Molecular Function (2): guanyl-nucleotide exchange factor activity (GO:0005085), protein binding (GO:0005515)

GO Cellular Component (3): acrosomal vesicle (GO:0001669), cytoplasm (GO:0005737), cytoplasmic vesicle (GO:0031410)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
hematopoietic or lymphoid organ development	2
gland development	1
hepaticobiliary system development	1
cellular process	1
tube development	1
digestive system development	1
GTP binding	1
GDP binding	1
GTPase regulator activity	1
binding	1
secretory granule	1
intracellular anatomical structure	1
cellular anatomical structure	1
cytoplasm	1
intracellular vesicle	1

Protein interactions and networks

STRING

814 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RCBTB2	LPAR6	P43657	641
RCBTB2	ITM2B	Q9Y287	629
RCBTB2	FNDC3A	Q9Y2H6	531
RCBTB2	CDADC1	Q9BWV3	517
RCBTB2	CYSLTR2	Q9NS75	489
RCBTB2	TSSK4	Q6SA08	489
RCBTB2	SETDB2	Q96T68	478
RCBTB2	AGTR1	P30556	470
RCBTB2	PHF11	Q9UIL8	465
RCBTB2	AFAP1L1	Q8TED9	463
RCBTB2	MLNR	O43193	460
RCBTB2	GRPEL2	Q8TAA5	459
RCBTB2	ZNF608	Q9ULD9	446
RCBTB2	PRSS55	Q6UWB4	436
RCBTB2	CAB39L	Q9H9S4	425

IntAct

61 interactions, top by confidence:

A	B	Type	Score
HDAC3	TBL1X	psi-mi:“MI:0914”(association)	0.760
FARS2	RCBTB2	psi-mi:“MI:0915”(physical association)	0.720
RCBTB2	FARS2	psi-mi:“MI:0915”(physical association)	0.720
IGF2BP1	IGF2BP3	psi-mi:“MI:0914”(association)	0.640
PIK3R2	IRS4	psi-mi:“MI:0914”(association)	0.640
RCBTB2	UBE2I	psi-mi:“MI:0915”(physical association)	0.560
UBE2I	RCBTB2	psi-mi:“MI:0915”(physical association)	0.560
RCBTB2	TAE1	psi-mi:“MI:0915”(physical association)	0.560
TAE1	RCBTB2	psi-mi:“MI:0915”(physical association)	0.560
RCBTB2	MORF4L1	psi-mi:“MI:0915”(physical association)	0.560
PLA2G6	RCBTB2	psi-mi:“MI:0915”(physical association)	0.560
RBBP9	RCBTB2	psi-mi:“MI:0915”(physical association)	0.560
RCBTB2	NUDCD2	psi-mi:“MI:0915”(physical association)	0.560
RCBTB2	RCBTB2	psi-mi:“MI:0915”(physical association)	0.550
TTK	RCBTB2	psi-mi:“MI:0915”(physical association)	0.400
USP10	RCBTB2	psi-mi:“MI:0915”(physical association)	0.400
VRK3	RCBTB2	psi-mi:“MI:0915”(physical association)	0.400
RUNX3	RCBTB2	psi-mi:“MI:0915”(physical association)	0.400
RCBTB2	HSP90AB1	psi-mi:“MI:0915”(physical association)	0.400
PDE4B	RCBTB2	psi-mi:“MI:0915”(physical association)	0.370
RCBTB2	COPS4	psi-mi:“MI:0915”(physical association)	0.370
ATXN2L	MCRIP1	psi-mi:“MI:0914”(association)	0.350
CAPRIN1	EIF3CL	psi-mi:“MI:0914”(association)	0.350
CLASP1	KIF2A	psi-mi:“MI:0914”(association)	0.350
CLASP2	TAF5L	psi-mi:“MI:0914”(association)	0.350

BioGRID (69): RCBTB2 (Two-hybrid), UBE2I (Two-hybrid), FARS2 (Two-hybrid), RCBTB2 (Affinity Capture-MS), RCBTB2 (Affinity Capture-MS), COPS4 (Two-hybrid), RCBTB2 (Two-hybrid), RCBTB2 (Affinity Capture-MS), RCBTB2 (Affinity Capture-MS), RCBTB1 (Affinity Capture-MS), RCBTB2 (Affinity Capture-MS), FECH (Affinity Capture-MS), RCBTB2 (Affinity Capture-MS), RCBTB2 (Affinity Capture-MS), RCBTB2 (Affinity Capture-MS)

ESM2 similar proteins: A0A2R8Q1W5, A2AAX3, A4IF63, A6QQY2, D3ZA50, D3ZQG6, F7H9X2, G3X9X1, O95199, P28575, P57790, Q14145, Q28DE7, Q2T9Z7, Q2WGJ6, Q56A24, Q58CV6, Q59H18, Q5BK60, Q5GIG6, Q5R774, Q5RCZ7, Q5RDY3, Q5U3Y0, Q5U580, Q5ZJU2, Q5ZLD3, Q684M4, Q6AYI2, Q6P798, Q6TFL4, Q6ZPT1, Q7TQP6, Q80TF4, Q80YG3, Q8BRG6, Q8BSF5, Q8IY47, Q8N7A1, Q8VEM9

Diamond homologs: A1L4W5, B7U179, B9DHT4, E9Q4F2, F7ASZ0, G5E8B9, M3XQV7, O22286, O43791, O94889, O95199, O95625, P17789, P28575, P42282, P57790, P58545, Q0IHH9, Q0V9W6, Q0VCW1, Q14145, Q1EBV6, Q2LE78, Q2M2N2, Q54D84, Q5BL35, Q5NVK7, Q5R774, Q5RCZ7, Q5TC79, Q5TZE1, Q684M4, Q6DEL7, Q6IQ16, Q6NRH0, Q6P8B3, Q6YCH2, Q6ZWS8, Q7T330, Q7ZX06

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 57 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal	5	14.6×	8e-03
EML4 and NUDC in mitotic spindle formation	5	11.6×	8e-03
Resolution of Sister Chromatid Cohesion	5	10.8×	8e-03
RHO GTPases Activate Formins	5	9.7×	8e-03
Mitotic Prometaphase	5	8.7×	9e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

80 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	70
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2039 predictions. Top by Δscore:

Variant	Effect	Δscore
13:48496185:CCTTA:C	donor_loss	1.0000
13:48496186:CTTA:C	donor_loss	1.0000
13:48496187:TTAC:T	donor_loss	1.0000
13:48499623:A:AC	donor_gain	1.0000
13:48499623:ACTG:A	donor_gain	1.0000
13:48499624:C:CC	donor_gain	1.0000
13:48499624:CTGC:C	donor_gain	1.0000
13:48501737:CTT:C	donor_loss	1.0000
13:48501738:TTACC:T	donor_loss	1.0000
13:48501740:A:AC	donor_gain	1.0000
13:48501740:ACCGA:A	donor_loss	1.0000
13:48501741:C:CC	donor_gain	1.0000
13:48501741:C:CG	donor_loss	1.0000
13:48501780:T:A	donor_gain	1.0000
13:48501864:AGGTT:A	acceptor_gain	1.0000
13:48501865:GGTT:G	acceptor_gain	1.0000
13:48501866:GTT:G	acceptor_gain	1.0000
13:48501867:TT:T	acceptor_gain	1.0000
13:48501868:TC:T	acceptor_loss	1.0000
13:48501869:C:CC	acceptor_gain	1.0000
13:48501869:CT:C	acceptor_loss	1.0000
13:48502719:CTTA:C	donor_loss	1.0000
13:48502720:TTACC:T	donor_loss	1.0000
13:48502722:A:AC	donor_gain	1.0000
13:48502722:AC:A	donor_gain	1.0000
13:48502723:C:CC	donor_gain	1.0000
13:48502723:CC:C	donor_gain	1.0000
13:48502723:CCCA:C	donor_gain	1.0000
13:48502910:TAATC:T	acceptor_gain	1.0000
13:48502916:T:G	acceptor_loss	1.0000

AlphaMissense

3603 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
13:48490234:G:C	C511W	1.000
13:48496211:C:G	A499P	1.000
13:48496269:G:C	C479W	1.000
13:48496306:G:T	A467D	1.000
13:48496318:A:G	L463P	1.000
13:48490120:A:C	F549L	0.999
13:48490120:A:T	F549L	0.999
13:48490121:A:G	F549S	0.999
13:48490122:A:G	F549L	0.999
13:48490139:G:T	A543E	0.999
13:48490140:C:G	A543P	0.999
13:48490151:A:G	F539S	0.999
13:48490222:G:C	C515W	0.999
13:48490224:A:G	C515R	0.999
13:48490225:A:C	F514L	0.999
13:48490225:A:T	F514L	0.999
13:48490227:A:G	F514L	0.999
13:48490235:C:T	C511Y	0.999
13:48490236:A:G	C511R	0.999
13:48496210:G:T	A499E	0.999
13:48496219:A:G	L496P	0.999
13:48496222:A:G	L495P	0.999
13:48496231:G:T	A492D	0.999
13:48496258:A:T	I483N	0.999
13:48496270:C:T	C479Y	0.999
13:48496271:A:G	C479R	0.999
13:48496282:A:G	L475S	0.999
13:48496307:C:G	A467P	0.999
13:48496309:A:G	L466S	0.999
13:48496315:A:G	L464P	0.999

dbSNP variants (sampled 300 via entrez): RS1000097334 (13:48517780 C>G), RS1000186103 (13:48532984 C>A,T), RS1000197989 (13:48536216 G>A), RS1000239366 (13:48504839 G>C), RS1000251667 (13:48534773 T>C,G), RS1000324781 (13:48492411 C>T), RS1000463841 (13:48498652 A>G), RS1000499211 (13:48522557 C>T), RS1000529645 (13:48517410 C>A), RS1000550019 (13:48506298 C>T), RS1000575112 (13:48503357 A>T), RS1000625884 (13:48500410 T>C,G), RS1000658628 (13:48500212 TAAG>T), RS1000687075 (13:48497095 C>T), RS1000751557 (13:48498506 G>A,T)

Disease associations

OMIM: gene MIM:603524 | disease phenotypes: MIM:612073

GenCC curated gene-disease

Mondo (1): mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria (MONDO:0012791)

Orphanet (1): Mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria (Orphanet:1933)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST009391_118	Metabolite levels	5.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0010354	diacylglycerol 36:1 measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C567624	Mitochondrial Dna Depletion Syndrome, Encephalomyopathic Form, With Methylmalonic Aciduria, Autosomal Recessive (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

40 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression	7
bisphenol A	affects cotreatment, increases methylation, decreases expression, decreases methylation, increases expression	3
Tretinoin	increases expression	3
methylmercuric chloride	decreases expression	2
sodium arsenite	affects expression, increases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Cyclosporine	decreases expression	2
GSK-J4	decreases expression	1
triphenyl phosphate	affects expression	1
sodium bichromate	decreases expression	1
potassium chromate(VI)	decreases expression	1
CGP 52608	affects binding, increases reaction	1
motexafin gadolinium	affects cotreatment, decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
belinostat	decreases expression	1
abrine	increases expression	1
dorsomorphin	decreases expression, affects cotreatment	1
gardiquimod	decreases reaction, decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Zoledronic Acid	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Air Pollutants, Occupational	decreases expression	1
Cisplatin	increases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Diethylhexyl Phthalate	decreases expression	1
Diuron	decreases expression	1
Drugs, Chinese Herbal	decreases expression	1
Ethyl Methanesulfonate	increases expression	1
Fluorouracil	affects expression	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TI65	HAP1 RCBTB2 (-) 1	Cancer cell line	Male
CVCL_XS18	HAP1 RCBTB2 (-) 2	Cancer cell line	Male
CVCL_XS19	HAP1 RCBTB2 (-) 3	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.